Westminster Health Forum policy conference:
Priorities for rare disease diagnosis, care and treatment in England
Timing: Morning, Thursday, 5th June 2025
*****Taking Place Online*****

Draft agenda subject to change

WESTMINSTER HEALTH FORUM

8.30 Registration

9.00 **Chair's opening remarks**
Baroness Neville-Jones

9.05 **'Four years of the UK Rare Diseases Framework – progress through England's Action Plans and commitments for 2025'**
Dr Kath Bainbridge, Head, Rare Diseases and Emerging Therapies, Department of Health and Social Care
Questions and comments from the floor

9.30 **Priorities for patient engagement in shaping rare disease policy**
Nick Meade, Interim CEO and Director, Policy, Genetic Alliance UK

9.40 **Strategies for improving early detection, diagnosis and care coordination**
priorities from the England Rare Diseases Action Plan 2025 | *delivering faster diagnostics and growing capacity* | *incentivising clinics for multi-system disorders* | *improving workforce awareness of rare diseases* | *equitable access to specialist care and treatment* | *innovative approaches to patient support* | *the future for specialised commissioning in NHS reform* | *priorities for the NHS Genomic Networks of Excellence* | *approaches to digitalising genomics*
Dr Emma Baple, Professor, Genomic Medicine and Medical Director, South West Genomic Laboratory Hub, University of Exeter
Dr Ed Miller, Education Specialist, Genomics Education Programme, NHS England
Dr Peter Fish, CEO, Mendelian
Stephanie Barton, Rare Disease Scientific Lead, North West Genomics Laboratory Hub; and Fellow, Royal College of Pathologists
Dr Amanda Cole, Rare Disease Parent Advocate; and Director, Office of Health Economics

10.10 Questions and comments from the floor

10.35 **Next steps for whole genome sequencing in newborn screening**
Professor Jim Bonham, President, International Society of Neonatal Screening
Questions and comments from the floor

11.00 **Chair's closing remarks**
Baroness Neville-Jones

11.05 Break

11.15 **Chair's opening remarks**
Senior Parliamentarian

11.20 **Advancing development of targeted therapies and genetic medicine pathways for rare diseases**
Dr Ana Lisa Tavares, Clinical Lead, Rare Disease Research, Genomics England
Questions and comments from the floor

11.45 **Priorities for Highly Specialised Technology evaluation and transparency**
Senior representative, guidance
Questions and comments from the floor

12.10 **The future for personalised treatments, innovative research, and clinical trials for rare diseases**
preparing the NHS to deliver personalised treatments | *addressing potential treatment eligibility issues* | *advancing rare disease medicine development* | *improving recruitment to clinical trials* | *regulatory and operational challenges in delivering highly personalised treatments* | *opportunities for national and international collaboration* | *priorities for data sharing of real world evidence* | *centring patient experience and safety* | *future pathways for accelerated, safe, and approved therapies*
Dr Simon Lande, CEO and Co-Founder, HealthLumen
Stephanie Caird, Partner, Mills & Reeve
Chris Bedford-Gay, Founder and Chairman, FOP Friends
Dr Bruce Bloom, Chief Collaboration Officer, Healx
Senior representative, research
Questions and comments from the floor

12.55 **Chair's and Westminster Health Forum closing remarks**
Senior Parliamentarian
Jessica Lear, Westminster Health Forum

This conference is supported by **HealthLumen**

HEALTH LUMEN